Household Transmission Dynamics of Multidrug Resistant Enterobacterales
NCT ID: NCT05798364
Last Updated: 2024-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
507 participants
OBSERVATIONAL
2023-05-19
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-Drug Resistant Bacteria Carriage After Travel
NCT03477760
Infection Risk Associated With Digestive MDRO Carriage in Hospitalized Patients
NCT07134270
Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli
NCT04574596
The Effect of Faecal Microbiota Transplantation (FMT) on Eradication of Multidrug Resistant Organisms (MRO) in Intestinal Carriers
NCT05742074
FMT for Multidrug Resistant Organism Reversal
NCT02312986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Quantifying and understanding the mechanisms of household transmission is of major importance to elaborate control strategies specifically designed to the community.
The main objective is to estimate the rate of confirmed transmissions of MDR-E from an index case to related household members.
The primary endpoint is defined by the secondary attack rate (SAR) for confirmed transmissions, i.e. the proportion of confirmed (based on genetic analysis of strains) acquisitions of MDR-E in all household members over the study period (three months).
Screening of eligible patients will rely on an automated daily request of all MDR-E positive samples that is already implemented in the participating centers.
Information on the study will be given to eligible patients, those who meet eligibility criteria and willing to participate will be asked to ive non-opposition.
Seven days before hospital discharge, index patients who consent to participate will provide a fecal sample to be screened for MDR-E carriage. If the patient is still positive at discharge for MDR-E fecal carriage, he/she will be included in the cohort (=index case). His/her household members (=HH members) will then be invited to participate and included after agreement.
After inclusion, index cases and household members will be prospectively followed-up for 3 months (+/-7 days), and asked to provide self-collected stool samples and questionnaires on day7, day15, day21, day30, month2 and month3.
Self-collected stool samples will be mailed to the reference microbiology laboratory (Bichat) with self-filled questionnaires.
In addition, in the context of the ancillary study:
To obtain accurate data on interactions between household members, Ultra Wide Band (UWB) systems will be used. During 4 days, index cases and household members will wear a small wireless sensor that records continuously the identity of other sensors that are in close proximity. For each household, recording will be performed on 2 week days and 2 week-end days (Saturday and Sunday).
Proportion of transmissions in all household members over the study period (SAR) and 95% confidence intervals will be calculated at the end of follow-up for both probable and confirmed transmissions and described according to household size and index-case population type. Kaplan Meier survival analysis will be used to estimate the median time to (first) acquisition among household members and a Cox shared frailty-model to study variables associated with acquisition index-case and household members' potential exposures, household's characteristics, MDR-E abundance in index case-patients, intestinal microbiota diversity and composition). Additionally, a stochastic individual based model to capture the multifactorial processes involved in MDR-E transmission will developed. Several models of increasing complexity will be built in order to compare their likelihood given the acquisitions observed over time in the different households. The model will be integrated in an inference framework to analyse the data and estimate model parameters (eg transmission rates for the different routes). The inference techniques will involve bayesian statistics, probably Markov Chain Monte Carlo with data augmentation. The different models will be compared based on specific criterion, such as the Deviance Information Criterion (DIC). The parameterized model selected in the preceding step will be used to simulate and assess different strategies of control of MDR-E emergence and transmission to households.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Index patients
Adults MDR-E carriers.
No interventions assigned to this group
Household members
Adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* adults (≥ 18 years)
* hospitalized in participating hospitals
* positive for MDR-E fecal carriage on routine screening during hospital stay
* with no documented MDR-E fecal carriage in the 12 months preceding current hospitalization
* regularly living with at least two additional household members who expressed their non-opposition to participate.
* planning to live in Ile de France for the next three months Household members
* adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion, and who expressed their non-opposition to participate.
* planning to live in Ile de France for the next three months
Exclusion Criteria
* Subject under legal protection (guardianship)
* Subject deprived of liberty under judicial constraint
* Subject undergoing psychiatric care
* Index member negative for MDR-E fecal carriage either before discharge (D-7 to D-2) or on day of discharge (D0)."
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kernéis Solen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bichat Hospital
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP220479
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.